

## Special Issue

# Metabolic and Genetic Associated Fatty Liver Diseases

### Message from the Guest Editors

This Special Issue of *Biomedicine*, entitled “Metabolic and Genetic Associated Fatty Liver Diseases”, will include a selection of articles (both original and review) focusing on the role of metabolic and genetic factors in non-alcoholic fatty liver disease (NAFLD) and its clinical consequences (progression to liver diseases as well as atherosclerotic cardiovascular disease—ASCVD). NAFLD is a highly prevalent disease and is usually accompanied by metabolic, inflammatory, coagulation, and blood pressure disturbances. Increasing evidence is questioning the role of fatty liver *per se* in causing ASCVD, suggesting that the pathogenesis of NAFLD might be crucial in influencing the different associated clinical consequences. We are seeking basic, clinical, and multi-disciplinary research that will aid in building the knowledge base of this topic and help fully characterize the mechanisms underlying the relationship between NAFLD and severe liver diseases or atherosclerosis processes.

### Guest Editors

Dr. Laura D'Erasmo

Department of Translational and Precision Medicine, University of Rome Sapienza, Viale del Policlinico 155, 00185 Rome, Italy

Dr. Alessia Di Costanzo

Department of Translational and Precision Medicine, University of Rome Sapienza, 00161 Rome, Italy

### Deadline for manuscript submissions

closed (30 April 2023)



## Biomedicines

an Open Access Journal  
by MDPI

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/si/111966](https://mdpi.com/si/111966)

*Biomedicines*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)

[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)





# Biomedicines

---

an Open Access Journal  
by MDPI

---

Impact Factor 3.9  
CiteScore 6.8  
Indexed in PubMed



[mdpi.com/journal/  
biomedicines](https://mdpi.com/journal/biomedicines)



## About the Journal

### Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

---

### Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

---

### Author Benefits

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPLus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

#### Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).